---
title: How I Treat Higher-Risk MDS
date: '2025-01-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39808802/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20250115170812&v=2.18.0.post9+e462414
source: Blood
description: Myelodysplastic syndromes/neoplasms (MDS) are a widely heterogenous group
  of myeloid malignancies characterized by morphologic dysplasia, a defective hematopoiesis,
  and recurrent genetic abnormalities. The original and revised International Prognostic
  Scoring Systems (IPSS) have been used to risk-stratify patients with MDS to guide
  treatment strategies. In higher-risk MDS, the therapeutic approach is geared toward
  delaying leukemic transformation and prolonging survival. For over a decade, ...
disable_comments: true
---
Myelodysplastic syndromes/neoplasms (MDS) are a widely heterogenous group of myeloid malignancies characterized by morphologic dysplasia, a defective hematopoiesis, and recurrent genetic abnormalities. The original and revised International Prognostic Scoring Systems (IPSS) have been used to risk-stratify patients with MDS to guide treatment strategies. In higher-risk MDS, the therapeutic approach is geared toward delaying leukemic transformation and prolonging survival. For over a decade, ...